评价 CD47 在前列腺癌抑制性肿瘤微环境和免疫治疗中的作用。

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.

机构信息

Department of Urology, School of Medicine, South China University of Technology, Guangzhou 510006, China.

Department of Urology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.

出版信息

J Immunol Res. 2023 Sep 9;2023:2473075. doi: 10.1155/2023/2473075. eCollection 2023.

DOI:10.1155/2023/2473075

PMID:37719086

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10505079/

Abstract

BACKGROUND

CD47 has high levels of expression in malignant cancer cells, which binds to SIRP- to release the "don't eat me" signal and prevents mononuclear macrophages from phagocytosing the cells. Resistance to drugs and metastases are potential barriers for prostate cancer endocrine therapy. Although immunotherapy for tumors has developed rapidly in the last few decades, its effectiveness in treating prostate cancer is unsatisfactory. Prostate cancer has a high-expression level of CD47. Therefore, a novel approach for potential immunotherapy may be provided by investigating the relationship among CD47 and the infiltration of immune cells in the prostate carcinoma.

METHODS

The GEPIA database was utilized to compare the abundance of CD47 in malignant tissues with tissues that were normal. Furthermore, the function of CD47 in prostate carcinoma was assessed by CancerSEA. The association among CD47 and the tumor microenvironment was assessed utilizing the TISCH single cell data database. By using TIMER, the connection among CD47 and immunological invasion of prostate cancer was explored. Moreover, macrophages were cocultured with mouse prostate cancer cell RM-1 blocked by CD47 antibody to observe the changes in phagocytosis efficiency .

RESULTS

Expression level of CD47 is upregulated in prostate carcinoma, and it is closely connected with prostate cancer's inadequate immune invasion. CD47 antibody blocking promotes macrophage phagocytosis of RM-1.

CONCLUSION

Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.

摘要

背景

CD47 在恶性癌细胞中高表达，与 SIRP-结合释放“不要吃我”信号，阻止单核巨噬细胞吞噬细胞。药物耐药和转移是前列腺癌内分泌治疗的潜在障碍。虽然肿瘤的免疫治疗在过去几十年中发展迅速，但它在治疗前列腺癌方面的效果并不令人满意。前列腺癌 CD47 高表达。因此，通过研究 CD47 与前列腺癌中免疫细胞浸润的关系，可能为潜在的免疫治疗提供新的方法。

方法

利用 GEPIA 数据库比较恶性组织与正常组织中 CD47 的丰度。此外，通过 CancerSEA 评估 CD47 在前列腺癌中的功能。利用 TISCH 单细胞数据数据库评估 CD47 与肿瘤微环境之间的关系。通过 TIMER 探讨 CD47 与前列腺癌免疫浸润的关系。此外，用 CD47 抗体阻断巨噬细胞与小鼠前列腺癌细胞 RM-1 共培养，观察吞噬效率的变化。